About Skye Bioscience
Skye Bioscience is a company based in San Diego (United States) founded in 2011. Skye Bioscience has raised $3.82 million across 20 funding rounds from investors including Driehaus, Hilco Vision and 5AM Ventures. The company has 16 employees as of December 31, 2024. Skye Bioscience has completed 1 acquisition, including Bird Rock Bio. Skye Bioscience offers products and services including Nimacimab. Skye Bioscience operates in a competitive market with competitors including GW Pharma, IGC Pharma, MIRA Pharmaceuticals, NEUROPATHIX and Agrithera, among others.
- Headquarter San Diego, United States
- Employees 16 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Skye Bioscience, Inc.
-
Annual Revenue
Not available
-
Net Profit
-$26.57 M (USD)29.43as on Dec 31, 2024
-
EBITDA
-$36.13 M (USD)-166.68as on Dec 31, 2024
-
Total Equity Funding
$3.82 M (USD)
in 20 rounds
-
Latest Funding Round
$40 M (USD), Post-IPO
Mar 13, 2024
-
Investors
Driehaus
& 6 more
-
Employee Count
16
as on Dec 31, 2024
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Skye Bioscience
Skye Bioscience is a publicly listed company on the NASDAQ with ticker symbol SKYE in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Skye Bioscience
Skye Bioscience offers a comprehensive portfolio of products and services, including Nimacimab.
Inhibits CB1 receptor to aid obesity and metabolic management
People of Skye Bioscience
Unlock access to complete
Unlock access to complete
Funding Insights of Skye Bioscience
Skye Bioscience has successfully raised a total of $3.82M across 20 strategic funding rounds. The most recent funding activity was a Post-IPO round of $40 million completed in March 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Skye Bioscience
Skye Bioscience has secured backing from 7 investors, including venture fund and institutional investors. Prominent investors backing the company include Driehaus, Hilco Vision and 5AM Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital fund backed incubator focused on the healthcare startups
|
Locked | Locked | Locked | |
|
Private equity and hedge fund investments in healthcare are managed.
|
Locked | Locked | Locked | |
|
Long-term investments in healthcare companies are managed by Altium Capital.
|
Locked | Locked | Locked |
Investor details for Skye Bioscience
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Skye Bioscience
Skye Bioscience has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Bird Rock Bio.
Investment portfolio details for Skye Bioscience
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Antibody therapeutics targeting G-Protein Coupled Receptors are developed and validated.
|
Locked | Locked | 2008 | Locked |
Complete acquisition details for Skye Bioscience
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Skye Bioscience
Detailed financials for Skye Bioscience
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Skye Bioscience Comparisons
Peer comparison for Skye Bioscience
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Skye Bioscience
Skye Bioscience operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as GW Pharma, IGC Pharma, MIRA Pharmaceuticals, NEUROPATHIX and Agrithera, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of cannabinoid medicines for MS spasticity, cancer pain and childhood epilepsy
|
|
| Locked | Locked | Locked |
Pharmaceutical products targeting neurological disorders like Alzheimer's are developed.
|
|
| Locked | Locked | Locked |
Cannabinoid-based therapeutics for chronic pain and anxiety are developed.
|
|
| Locked | Locked | Locked |
Developer of therapeutics targeting inflammation, neurodegeneration, oxidative stress, and neuropathic pain
|
|
| Locked | Locked | Locked |
Cannabis-based therapeutics are developed for pain and neurological disorders.
|
Detailed competitors of Skye Bioscience
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Skye Bioscience
Complete news archive for Skye Bioscience
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Skye Bioscience
Skye Bioscience was founded in 2011 and raised its 1st funding round 1 year after it was founded.
Skye Bioscience is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Punit Dhillon is the current CEO of Skye Bioscience.
Skye Bioscience is a funded company, having raised a total of $3.82M across 20 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Skye Bioscience is 16.
Founded in 2011 and based in San Diego, United States, cannabinoid-based therapies targeting the endocannabinoid system are developed by the company for glaucoma, ocular hypertension, and additional diseases. Operations focus on pharmaceutical candidates such as THCVHS, a prodrug of tetrahydrocannabinol formulated for topical ocular use, and CBDVHS, an analog of cannabidiol with various therapeutic potentials. The biotech sector is served through these endocannabinoid-modulating treatments.
Skye Bioscience's top competitors include IGC Pharma, MIRA Pharmaceuticals and GW Pharma.
Skye Bioscience offers Nimacimab.
Yes, Skye Bioscience is publicly traded on NASDAQ under the ticker symbol SKYE.
Skye Bioscience has made 1 acquisition, including Bird Rock Bio.
Skye Bioscience has 7 investors. Key investors include Driehaus, Hilco Vision, 5AM Ventures, Ally Bridge Group, and Sphera Fund.
The ticker symbol of Skye Bioscience is SKYE on NASDAQ.